CFR Chemaphor Inc.

About 250 Veterinary Clinics and close to 2000 dogs are now trying Oximunol™ Chewable Tablets, a unique new product for dogs from Avivagen Animal Health ("Avivagen") that improves gastrointestinal health as well as coat quality and decreases shedding.

"This is a very significant accomplishment in just over three months when you consider that we launched our first commercial product in November," comments Dave Hankinson, CEO of Avivagen. "We are seeing growth as clinics move from trial product to restocking orders," Hankinson confirms.

In addition to strong trial support from veterinary clinics, a new 50-Day Challenge was recently launched on the Avivagen website at www.avivagen.com to help accelerate the product introduction to consumers. The challenge allows any dog owner to sign up for a free trial bottle of 50 Oximunol™ Chewable Tablets. Participants are asked to fill out a short questionnaire before and at the end of the 50 day trial to allow Avivagen to monitor the results.

"We encourage dog owners to try the product because in most dogs, the results speak for themselves," Hankinson says. "The beauty of Oximunol™ Chewables is that when owners see the benefits, they want their dog to stay on the product. These pet parents then visit their veterinarian to obtain additional supplies of Oximunol™ Chewable Tablets. This is starting to translate into sales growth for Avivagen."

Other significant milestones in the first three months of operation include launching an Avivagen blog as well as establishing a strong presence on Facebook (http://www.facebook.com/pages/Avivagen-Animal-Health/173599769320245) and Twitter (@avivagen). Twitter followers already total more than 900.

Guest blogger for Avivagen Animal Health, David Bannister, is one of those who discovered the real benefits through his own experience with the product. "First of all, I want to state up front that I have written much of the copy that Avivagen uses in their material about Oximunol™ Chewable Tablets because I work as a copy writer for their agency," Bannister explains. "I'm as skeptical as the average consumer about new product claims, and likely even more so.

"My wife, Anne and I have a 10-year-old chocolate Lab named Holly, who is a shedding machine. Anne would have to Swiffer around the edges of our hardwood floors every two days to keep on top of the accumulating fur that roamed around the house like tumbleweeds!

"By the time Holly was on Oximunol™ Chewable Tablets two weeks, we were already seeing a reduction in the amount of hair accumulating on the floor and other surfaces. At 50 days, the reduction in shedding is very significant... We're guessing it's only about 1/4 of the amount Holly used to shed. Anne no longer feels compelled to Swiffer every couple of days. Holly's coat looks shiny and feels softer as well.

"I am now fully convinced that dog owners who experience substantial shedding from their pets will find Oximunol™ Chewable Tablets a great relief. We plan to keep Holly on it and I encourage other dog owners to try it and see the results for themselves," Bannister adds.

"All the early signals for Avivagen and Oximunol™ Chewable Tablets are positive," comments Hankinson. "We are on track and I am very satisfied with the progress we have made in the short time since we launched."

"Stay tuned. We are planning to give our stakeholders and shareholders more frequent and regular updates in this acceleration phase," Hankinson concludes.

Avivagen is a new Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials and sold exclusively through veterinarians. Avivagen is a subsidiary of Chemaphor Inc., a Canadian company dedicated to the research and development of science-based, natural products for people and animals.

Chemaphor is listed on the TSX Venture Exchange and trades under the symbol CFR.

™Trademark of Chemaphor Inc.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above. Anyone interested in the treatments described above should discuss the potential benefits and risks of such treatments with their veterinarian.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: David Hankinson CEO, Avivagen Animal Health 902-825-9270 Graham Burton, PhD President and Co-Founder Chemaphor Inc. 613-990-0969 Investor Relations: Evolution Group Inc. Sylvain Archambault 514-448-4887/Toll free: 866-703-4887 s.archambault@evolutiongrp.com www.evolutiongrp.com